PARADIGM SHIFTING DRUGS

FOR LIFE-THREATENING
BLOOD DISEASES

PARADIGM SHIFTING DRUGS

FOR BLOOD DISEASES

OUR

MISSION

Aronora is a clinical stage biopharmaceutical company committed to developing and commercializing novel medicines for blood diseases with significant unmet medical need. We have a talented and dedicated team of scientists and clinicians with extensive experience in pharmaceutical product development, from discovery through commercialization. Our robust pipeline of innovative product candidates target disease modifying pathways with unique mechanisms of action. We aim to bring these exciting new therapies to patients in need.

OUR

MISSION

Aronora is a clinical stage biopharmaceutical company committed to developing and commercializing novel medicines for blood diseases with significant unmet medical need. We have a talented and dedicated team of scientists and clinicians with extensive experience in pharmaceutical product development, from discovery through commercialization. Our robust pipeline of innovative product candidates target disease modifying pathways with unique mechanisms of action. We aim to bring these exciting new therapies to patients in need.

LEADERSHIP

TEAM

LEADERSHIP

TEAM

andras gruber md aronora

Andras Gruber, M.D., President & CEO
Co-founder of Aronora, and chief executive officer since incorporation of the company in 2012. Dr. Gruber served as a clinician scientist at Semmelweis University, faculty at The Scripps Research Institute, director of medical affairs at DepoTech/Skyepharma, chief medical and scientific officer of Pharmanetics, and research professor at Emory University before joining Oregon Health & Science University, where he is currently professor of biomedical engineering and medicine. He is inventor of or materially contributed to the development of several drugs, including antithrombotic agents, chemotherapeutics, and analgesics, as well as Aronora’s fundamentally new product concepts. Dr. Gruber has established important corporate and scientific partnerships, and raised significant funds for Aronora’s drug discovery and development activities.

erik tucker phd aronora

Erik I. Tucker, Ph.D., COO & CFO
Co-founder of Aronora, serving as both Chief Operating Officer and Chief Financial Officer since 2012. Dr. Tucker is a talented scientist and entrepreneur, having led his team from product discovery to two INDs and four successful clinical trials. He has 12 issued patents, authored >40 scientific articles, and has raised >$50 million of non-dilutive funding through a combination of small business grants from the National Institutes of Health SBIR program, a strategic alliance with Bayer, and a royalty monetization deal with XOMA Corporation. He is also an experienced angel investor, federal grant reviewer, and bioscience mentor. Dr. Tucker received his B.S. from the University of Oregon and Ph.D. in biomedical engineering from Oregon Health & Science University. He also holds and adjunct faculty position in biomedical engineering within OHSU’s School of Medicine.

andras gruber md aronora

Andras Gruber, M.D., President & CEO
Co-founder of Aronora, and chief executive officer since incorporation of the company in 2012. Dr. Gruber served as a clinician scientist at Semmelweis University, faculty at The Scripps Research Institute, director of medical affairs at DepoTech/Skyepharma, chief medical and scientific officer of Pharmanetics, and research professor at Emory University before joining Oregon Health & Science University, where he is currently professor of biomedical engineering and medicine. He is inventor of or materially contributed to the development of several drugs, including antithrombotic agents, chemotherapeutics, and analgesics, as well as Aronora’s fundamentally new product concepts. Dr. Gruber has established important corporate and scientific partnerships, and raised significant funds for Aronora’s drug discovery and development activities.

erik tucker phd aronora

Erik I. Tucker, Ph.D., COO & CFO
Co-founder of Aronora, serveing as both Chief Operating Officer and Chief Financial Officer since 2012. Dr. Tucker is a talented scientist and entrepreneur, having led his team from product discovery to two INDs and four successful clinical trials. He has 12 issued patents, authored >40 scientific articles, and has raised >$50 million of non-dilutive funding through a combination of small business grants from the National Institutes of Health SBIR program, a strategic alliance with Bayer, and a royalty monetization deal with XOMA Corporation. He is also an experienced angel investor, federal grant reviewer, and bioscience mentor. Dr. Tucker received his B.S. from the University of Oregon and Ph.D. in biomedical engineering from Oregon Health & Science University. He also holds and adjunct faculty position in biomedical engineering within OHSU’s School of Medicine.